U.S. Stent Wars Cool, With New Products Held Up By FDA
This article was originally published in The Gray Sheet
Executive Summary
Volatility in the U.S. drug-eluting stent market seems to have settled down, with Boston Scientific maintaining a slim lead over sole competitor Johnson & Johnson/Cordis